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Abstract The chicken chorioallantoic membrane (CAM)
is a simple, highly vascularized extraembryonic membrane,
which performs multiple functions during embryonic
development, including but not restricted to gas exchange.
Over the last two decades, interest in the CAM as a robust
experimental platform to study blood vessels has been
shared by specialists working in bioengineering, develop-
ment, morphology, biochemistry, transplant biology, can-
cer research and drug development. The tissue composition
and accessibility of the CAM for experimental manipula-
tion, makes it an attractive preclinical in vivo model for
drug screening and/or for studies of vascular growth. In this
article we provide a detailed review of the use of the CAM
to study vascular biology and response of blood vessels to a
variety of agonists. We also present distinct cultivation
protocols discussing their advantages and limitations and
provide a summarized update on the use of the CAM in
vascular imaging, drug delivery, pharmacokinetics and
toxicology.
Keywords Angiogenesis  Anti-vascular therapies 
Chicken chorioallantoic membrane  Bioengineering 
Lymphangiogenesis  Organ transplantation  Physical
forces  Tumor vasculature
Abbreviations
AA Anti-angiogenic
AC Anti-cancer
ALA Aminolevulinic acid
AM Anti-microbial
AMD Age-related macular degeneration
BrdU Bromodeoxyuridine
CAM Chicken chorioallantoic membrane
CNV Subfoveal choroidal neovascularization
DDS Drug delivery systems
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General information
Introduction
The visibility, accessibility, and rapid developmental
growth of the chorioallantoic membrane (CAM) offer clear
advantages to study and manipulate vascular functions. The
first use of the system dates of 1911 when Rous and
Murphy demonstrated the growth of chicken sarcoma
tumors transplanted onto the CAM [1]. One year later,
Murphy published successful heterologous transplantations
of tumors in this model [2].
In 1930s the CAM was first exploited for cultivation of
viruses and bacteria [3–5]. Its application in vascular-
related questions occurred only several decades later, but it
quickly gained recognition as an excellent model system
for studies associated with vascular responses.
The initial vascular-related experiments employed grafts
from tumors [1, 2] and later methylcellulose discs in which
compounds were encapsulated to determine induction of
vessel growth or inhibition by morphological criteria [6–8].
These discs provided a venue for the slow release of pro- or
anti- angiogenic factors and thus, a ‘‘high’’ throughput
platform for therapeutic exploration emerged. Problems
with this method were associated with the difficulty in
distinguishing the existing from the newly-formed (or
induced) capillaries. In addition, the methylcellulose discs
by itself could, on occasion, induce angiogenesis even in
the absence of growth factors, particularly if crystals of salt
were present. Thus, the approach was subsequently
replaced by 3D models of vascular invasion and other
alternatives [9, 10].
In addition to angiogenesis screens, the CAM has been
used to explore hemodynamics, immune cell trafficking,
transplantation and responses to therapy. In this review we
will provide a comprehensive summary of the use of this
model to study vascular-related questions bringing into this
description a rigorous evaluation of the pros and cons.
Structure and development of the CAM
The CAM develops in a similar manner as the allantois in
mammals as it extends extra embryonically from the ven-
tral wall of the endodermal hind-gut (Fig. 1). However, in
birds it also fuses with the chorion to form the chorioa-
llantoic membrane. Initially avascular, it quickly gains a
rich vascular plexus (Fig. 2a, b) that rapidly acquires
hierarchic complexity with the emergence of arteries and
veins (Fig. 2c). The growth of the CAM occurs from
embryonic development day 3 (stage 18 of Hamburger and
Hamilton, [11] ) and it is completed by day 10 (Fig. 3)
however, it is only fully differentiated by day 13. This
growth requires impressive rates of cell division with short
cell cycles. While this has not been significantly explored,
bromodeoxyuridine (BrdU) incorporation revealed rapid
cell cycles and extensive proliferation (Fig. 4).
The CAM functions as the respiratory organ of avian
embryos. Although most of attention is given to the vas-
cular system, it is important to emphasize that the CAM
has a fully developed lymphatic system that holds
remarkable functional and molecular similarities to mam-
malian lymphatics [12]. A more detailed description of
lymphatic development in the CAM will be presented later
in the review.
Fig. 1 Chicken embryo and associated extra-embryonic structures.
a Chicken embryo at day 4 post-fertilization. Note the highly
vascularized chorioallantoic membrane (CAM) that expands from the
hind-gut. The yolk sac membrane (YSM), also highly vascularized, is
seen in the background; b Embryo at day 12 post-fertilization into a
10 cm petri dish. Note the significant growth of the CAM that now
exceeds the area covered by the yolk. The YSM is also present, but
under the embryo and only associated with the yolk
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Histologically, the CAM consists of two epithelial
sheets that limit a thin layer of stroma (Fig. 5). The upper
epithelium is of ectodermal origin, while the stroma and
the lower epithelium are of mesodermal and endodermal
origin respectively. It is within the stroma that the blood
vasculature and lymphatics reside. In this manner, it is
important to realize that any compound delivered on the
surface of the CAM has to pass across the surface epithe-
lium and reach the vessels in the stroma. Poor humidity
conditions when the CAMs are cultured ex ovo induce
significant cell division and keratinization of this upper,
and normally single, epithelial layer; making it even more
difficult to deliver soluble molecules to the underlying
vascular tree. Therefore the humidity status is critical
during the experimental use of this system.
It is important not to mistake the CAM with the yolk
membrane, which is also highly vascularized. This second
membrane is associated with the yolk and it has distinct
properties. Figure 1 clearly shows both membranes, that
are easily distinguishable in the young embryos and less
noticeable in an older embryo (Fig. 1). In the egg, the
CAM attaches to the surface of the egg shell, removing
calcium and obtaining oxygen for the atmosphere across
the porous shell. The attachment of the CAM to the shell
inner membrane occurs shortly after fertilization (day 4–5)
and thus, opening fertilized eggs for cultivation has to be
done by day 3, as after this time, rupture of the shell is
associated with rupture of the CAM. Also when opening
small windows for application of compounds at latter time
points, meticulous dissection of the shell and its underlying
membrane is necessary to expose the vascular CAM
without damaging small vessels.
Advantages and disadvantages of the CAM model
As already stated, the CAM model offers multiple advan-
tages over other in vivo models used to study angiogenesis
and vascular biology. The most prominent advantage of the
model is its accessibility and rapid growth (see Table 1).
Fig. 2 Images illustrating the maturation of the CAM vasculature.
a Primitive vascular plexus at day 3 post-fertilization; b Vascular
remodeling, growth and anastomosis can be seen at day 7 post-
fertilization; c Hierarchic vascular structures and fully differentiated
vessels are noted at embryo development day 10
Fig. 3 Expansion of the CAM was measured daily. Graph shows the
average of 5–7 CAMs per time point after plating the fertilized eggs
into a 10 cm petri dish (±SD). Note the exponential growth between
days 3 and 10
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The CAM develops in a short time from a small avascular
membrane into a structure that covers the entire inner
surface of the shell displaying a densely organized vascular
network. This process occurs over a period of only 7 days
(day 3–10). It is this enormous angiogenic boost provides a
wealth of information related to required developmental
pathways. In addition, this model can also be used to study
pathological processes by simple exposure to cytokines,
hormones or drugs, or by transplantation of tissues, isolated
cells or materials.
The great accessibility of the CAM and the easy han-
dling of the model for both intervention and imaging of the
vasculature have attracted many researchers. In particular,
the broad applicability of distinct imaging modalities that
range from microscopic- to magnetic resonance- to posi-
tron emission tomography imaging (MRI and PET) offer
multiple benefits. In addition, due to the transparency of its
superficial layers, nearly any wavelength in the visible part
Fig. 4 Proliferation kinetics of
CAM vessels. a Quantification
of BrdU incorporation in CAM
vessels at the indicated days
post-fertilization. Counts per
time point were the average of
positive nuclei in the vessels
from 3 to 4 CAMs per time
point; b Example of images
used to obtain the
measurements. The upper panel
represents embryo development
at day 4 and lower panel is an
example of embryo
development at day 6
Fig. 5 Immunohistochemical visualization of a-smooth muscle actin
(dark brown) in a transversal CAM section. Smaller capillary plexus
is more superficial in comparison to the larger vessels located deeper
in the CAM. (Color figure online) Fig. 6 Angiogram of the CAM lymphatic system. Lymphatic vessels
around a large blood vessel were visualized by FITC-dextran
fluorescence angiography (25 mg/kg; 20 kDa, kex = 470 ± 20 nm).
At a more superficial plane small non-fluorescent blood vessels are
also visible. Bar = 20 lm
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Table 1 Advantages and disadvantages of the CAM model as a screening platform
General biology
Advantages
Ease of use
Feasibility of carrying out multiple tests on individual CAMs
Rapid vascular growth
Real-time visualization of the assays
Complete accessibility to the circulatory system (for delivery of molecules intravascularly)
In vivo environment
Excellent modeling of more complex systems
No requirement for animal protocol approval (country dependent)
Disadvantages
Chicken-origin of the assay limits availability of reagents
CAM itself is undergoing rapid changes both morphologically and in terms of the gradual change in the rate of endothelial cell
proliferation during the course of embryonic development
Immunodeficiency
Contains a well-developed vascular network, which makes it difficult to discriminate between new capillaries and already existing ones
Sensitive to environmental factors
Differences in drug metabolism with mammals
Shell dust (or other irritants) can induce angiogenesis
Methodology
Advantages
Monitoring throughout the course of the assay
Rapid screening platform
Accessibility to vessels of different caliber and types
Reproducibility and reliability
Cost-effectiveness
Disadvantages
Specie-related differences need to be taken into account in interpreting results obtained in experimental animals
Complex choice of protocols available
Alternative drug metabolism/pharmacokinetics when compared to other in vivo (mammalian) models
Oral drug administration can not be tested
Post grafting non-specific inflammatory reactions that my induce a secondary vasoproliferative response
Short post-treatment observation time
Fig. 7 Images of human A2780
ovarian carcinoma grown on the
CAM. a Bright field image;
b Fluorescence angiography
(FITC-dextran,
kex = 470 ± 20 nm,
kem = 520 nm). Functional
vasculature of the CAM is
integrated well in the tumor.
Bar = 1 mm
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of the electromagnetic spectrum can be used for fluores-
cence imaging. For applications related to transplantation,
an important benefit is the slow developmental progression
of the immune system that reaches physiological activity
only by day 15 post-fertilization [13]. Thus, unwanted
immunological reactions are limited, facilitating the
transplantation of xenogeneic tissues, e.g. human tumors.
Last but not least, the cost-effectiveness of the model
adds to the long-list of benefits. In fact, the price of a
fertilized egg is 100 times lower than that of a mouse of a
common strain.
Nonetheless there are also limitations. Perhaps the most
prominent being the limits on the number of reagents
compatible with avian species, including antibodies, cyto-
kines and primers which might not work in chick tissues.
Along these lines, genetic manipulation, albeit possible
through virus, it is not as ‘‘easy’’ as in mice.
The CAM contains already a well-developed vascular
network, which makes it difficult to discriminate between
new capillaries and already existing ones. Another limita-
tion is that if experiments extend after 15 days, a non-
specific inflammatory reaction can occur that may limit the
success of grafting. Such reactions may provoke angio-
genic responses, which are difficult to distinguish from an
angiogenic activity of grafted material [7].
Cultivation protocols
Several protocols are available for culturing avian
embryos. The type of experiment to be conducted directs
the choice of the protocol. In many cases, investigators
rupture the egg and transfer the embryo to a 10 cm petri
dish at day 3 post-fertilization. This ex ovo culture of the
embryo, also called shell-less embryo culture offers ample
observation and manipulation space, allowing for testing of
several samples in a single CAM. For this approach, the
eggs are first kept at 38 C in a humidified incubator (days
0–3) on the side to ensure the position of the embryo is
opposite to where the cracking of the shell occurs. Subse-
quently, a small whole is made on the side of the air
chamber to equilibrate pressure and the egg is cracked into
a petri dish. Naturally, the exposure of the entire embryo
and yolk requires sterile conditions. Also removing the
embryo from the shell is associated with a low survival
rate, due to the frequent rupture of the yolk membrane
either during or after culture. This occurs due to excessive
distension of the yolk in the flat dish (Fig. 1b) [6, 8]. Ex
ovo survival rates can be drastically improved through
reducing the impact during the cracking of the egg shell
and placing the embryo in a confined curved space rather
than a flat petri dish for culture. Gentle cracking of the egg
can be achieved using a circular saw rather than cracking
the egg against a sharp edge (Fig. 8a). Alternative
cultivating dishes include large weight boats (Fig. 8b) and
plastic inserts that can be placed inside 100 mm petri
dishes to introduce a curvature to the dish (Fig. 8c). In
addition, it is paramount to keep the humidity in the
incubator at 98 % or higher and to maintain the culture
environment sterile. Using these approaches the viability is
around 50 % at day 14. For a demonstration of a refined
chick ex ovo culture and CAM assay with survival rates
over 50 % refer to the video article of Dohle et al. [14].
In ovo cultivation is an important alternative that
improves significantly the survival of the embryos. Fertil-
ized eggs are transferred to the incubator equipped with an
automatic rotator for 3 days. Turning prevents the embryo
from sticking to the shell membranes, as it would if it is left
in one position too long. Good results can be obtained by
turning the eggs the first thing in the morning, again at
noon, and the last thing at night. Alternatively, the use of
an automatic rotator enables slow but constant movement
of the eggs.
The process of in ovo cultivation is initiated also at day
3 post-fertilization. At this time, a hole of approximately
3 mm in diameter should be created in the eggshell with a
sterile tweezers and covered with a laboratory wrapping
film to prevent dehydration and possible infections
(Fig. 8d). The eggs are then returned to the incubator with
a relative air humidity of 65 % and a temperature of 37 C
in a static position until use (Fig. 8e). This initial small
incision changes the pressure inside the egg and prevents
binding of the CAM with the shell membrane. At day 7 or
later, the hole is extended to a diameter of approximately
3 cm in order to provide access to the chorioallantoic
membrane (Fig. 8f). This approach still enables experi-
mentation through a window and it offers an almost
unchanged physiological environment for the developing
embryo.
Depending on the country and regulations that provide
oversight to the use of animals, avian embryos are allowed
to develop until the hatching stage, usually at day 21 after
fertilization. This cultivation protocol has been used
broadly e.g. to study vascular development and (pro/anti)
angiogenesis, tumor growth and metastatic progression,
and to evaluate the effect of chemo-, radiation-, and pho-
todynamic therapies, see Table 2.
CAM as a screening platform
The CAM has served as an in vivo platform for experi-
mentation for more than 50 years. This system has been
used for the study of vascular development and angio-
genesis, tumor growth and metastasis [32], respiratory
properties [33], ion transport [34, 35], selective vascular
occlusion therapies, biocompatibility of engineered
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materials, drug distribution and toxicology. Next we
review this literature and delve into the methodology used
to provide readers with choices for future experimentation.
Vascular development and angiogenesis
As previously discussed, because of its rapid vascular
growth, the CAM has been the model of choice to evaluate
the effect of a wide number of compounds on growing
vessels. Many pro- and anti-angiogenic agents have been
tested by quantifying the morphological responses of the
CAM vasculature. These compounds have included growth
factors [6, 36], hormones [37, 38], natural molecules, anti-
cancer agents [39], gases [40], organometallic compounds
[41–43], pro-angiogenic molecules [37], antibiotics [44],
antibodies and synthetic small molecules [7, 36, 45, 46].
The efficacy of such compounds has been evaluated using
both qualitative and quantitative methods based on the
assessment of the vascular morphology and density. Ini-
tially, this was done by scoring the extent of vasculariza-
tion on a graded scale of 0–4 [47]. Alternatively, vascular
Fig. 8 CAM cultivation protocols. The ex ovo protocol (a–c) requires
(a) a gentle cracking of the egg using a blade and transferring of the
contents into a petri dish or weighing boats (b) with plastic a plastic
cover (c). The in ovo cultivation (d–f) starts with gentle rotation for
3 days. On embryo development day 3 the eggshell is opened with a
sterile tweezers (d) and subsequently covered with a laboratory
wrapping film (e). On the day when the experiment starts, the shell
above the air pouch of the egg is extended to a diameter of
approximately 3 cm (f) enabling further experimental manipulation
Table 2 Broad applicability of the CAM in vascular assays
Year Model Ref.
In ovo
1933 Grafting; artificial air sac technique (NAST) [15]
1956 Tumor growth in the CAM and embryo [16]
1956 ‘‘Zwilling-CAM’’ [17]
2001 One-photon excitation PDT [18–20]
2004 Radiosensitizing activity [21, 22]
2004 Experimental metastasis [23]
2003 Tissue engineering; ‘‘CAM cylinder model’’ [24]
2003 Angiogenesis [25]
2006 Angiogenesis [26]
Ex ovo
1974 Angiogenesis [8]
1974 Angiogenesis [27]
1987 ‘‘Artificial egg’’; teratogenicity [28]
2007 Two-photon excitation photodynamic therapy
(PDT)
[29]
2008 Angiogenesis [30]
2011 Gene transfer/angiogenesis [31]
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growth was also assessed by quantifying the number of
vessels that invaded, against gravity, an avascular matrix in
which pro-angiogenic compounds were casted (Fig. 9a–c)
[9, 10]. Injection of either fluorescent compounds or con-
trasting agents (India ink) favored visualization and eased
the quantification (Fig. 9d).
More recently, a number of attractive imaging tech-
niques (Table 3) were applied to the CAM to facilitate
visualization and offer objective quantification. Even MRI
and PET imaging have been used, but the resolution of
these techniques might not be sufficient for the identifica-
tion of vascular structures (Fig. 10).
Several visual vessel-counting methods [61] or auto-
mated approaches [62–64] have been also developed
(Table 4). Quantification, has frequently relied on
descriptors such as vascular density [62, 65], vessel
branching points/mm2 [64, 66], vascular length [67], or
endpoint density/mm2 [68, 69], see Table 4. An example of
automatic in vivo and in ovo quantification technique
developed by Nowak-Sliwinska et al. is presented in
Fig. 11.
Gene expression profiling associated with the physio-
logical CAM development [70], as well as with the
angiogenic switch during experimental tumor progression
[71] has been reported, but the lack of initial sequence
information for the chick has limited the use of this more
bFig. 9 Angiogenesis assays in the CAM. a Scheme of angiogenic
growth into an avascular matrix. This assay requires growth against
gravity and invasion into specific polymerized extracellular matrices.
A variety of matrices can be used for this purpose; b Nylon mesh
squares (pore size 250 lm; Tetko Inc) supporting a polymerized
collagen gel containing FGF2 were placed on top of the CAM. The
matrix on the left includes, in addition to FGF2, an anti-angiogenic
factor (Thrombospondin1) the one on the right has a mixture of FGF2
and VEGF. The CAM was injected with india ink to visualized small
vessels; c Higher magnification showing the small vessel inside the
previously avascular matrix; d The CAM can also be injected with
dextran-FITC to visualize angiogenic vessels
Table 3 Imaging techniques used for the CAM and/or chicken
embryo visualization
Imaging technique Ref.
Optical doppler tomography (ODP) [48]
Laser doppler perfusion imaging [49]
Optical coherence tomography (OCT) [50]
Spectroscopic OCT combined with and speckle variance
OCT
[50]
Intravital videomicroscopy (IVVM) [51,
52]
Scanning electron microscopy (SEM) [53]
Magnetic resonance imaging (MRI) [54]
Positron emission tomography (PET) [55]
Fluorescent confocal microscopy [56]
Photoacoustic tomography (PAT) [57]
Biotinylated lipid-coated microbubble spectroscopy [58]
Optically sectioned fluorescence HiLo endomicroscopy [59]
Fractal analysis of arborization [60]
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molecular approach. Instead these types of studies have
accelerated more in the retina (77).
Lymphangiogenesis
Lymphangiogenesis in the CAM emerges during mid-
development (days 5–9 post-fertilization) following the
initial growth of the blood vascular system and via
expansion of blind-ended sprouts [79]. Isolated lymphatic
endothelial progenitor cells are recruited to the tips of
growing vessels and grafting quail-chicken chimera
experiments showed unequivocally that the allantoic
mesoderm has lymphangiogenic potential [12]. Concurrent
to haemangiogenesis expansion, lymphatic vessels enlarge
and split offspring vessels, accompanied by transient cap-
illary expression of alpha smooth muscle actin (SMA) and
recruitment of polarized mural progenitor cells. VEGF-A
and hepatocyte growth factor (HGF) are well known
angiogenesis inducers in normal and pathologic conditions.
Cimpean et al. [80] showed that VEGF-A/HGF combina-
tion was able to promote a strong angiogenic response and
expression of prospero homeobox protein 1 (Prox1) in the
lymphatic endothelial cells of the CAM.
The lymphatics of the chorioallantoic membrane (CAM)
are drained by lymphatic trunks of the umbilicus that are
connected to the posterior lymph hearts. Intra-embryonic
Fig. 10 Selected imaging techniques used to visualize the CAM
vasculature of chicken embryo. a Confocal microscopy after blue
fluorescent polymer injection, by Dr. Grace Lee and Dr. Steven, with
permission from Mentzer’s lab [231]; b light microscopy of Smallpox
virus pocks on the CAM (from Public Health Image Library);
c Scanning electron microscopy (unpublished data, courtesy of Dr.
Valentin Djonov, Bern, Switzerland); d fluorescence microscopy
(with green fluorescent plasma marker and orange fluorescent flow
tracers), by Dr. Kenji Chamoto and Dr. Steven Mentzer, with
permission from Mentzer’s lab [231]; e non-invasive imaging of
in vivo blood flow velocity using optical Doppler tomography, with
permission from Chen et al. [48]; f Cells escaping CAM primary
tumors were visualized in the embryos with the vasculature
highlighted with red fluorescent-tagged LCA, with permission from
Springer [73]; g Fluorescence (red) distribution in the vessels by
means of laser scanning microscopy (phase contrast image (green),
with permission from Elsevier [232]; h co-registered PET and CT
images of a chicken embryo in the shell after 18F-Na injection, with
permission. This research was originally published in JNM. Warnock
et al. [55].  by the Society of Nuclear Medicine and Molecular
Imaging, Inc. (Color figure online)
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Table 4 Summary quantification techniques to assess capillary networks
Method System Descriptor Ref.
Vessel level
Semi-quantitative CAM vasculature Radius of the growth inhibition zone in 0-4 grades [47, 72]
Quantitative Implanted collagen Gels Vessel number growth vertically into the
implanted collagen gels
[9, 73]
Semi-quantitative Irritants applied topically on the CAM Vessel diameter [74]
Manual Morphometric analysis vessel diameter and length [75]
Semi-quantitative Fluorescent confocal microscopy Vessel density [56]
Automatic Developing/mature CAM Branching points/mm2 [64] [62, 69]
Capillary level
Semi-automatic Corrosion casting in scanning electron microscopy Capillary length, diameter, density [76, 77]
Automatic Developing/mature CAM Branching points/mm2 [19, 64]
Manual Post-fixation cross section analysis Number of capillary length [78]
Fig. 11 Schematic representation of an image processing procedure
used to characterize the CAM vascular network; a The original 16-bit
image; b The same image after the ‘‘first phase’’ thresholding to
extract main vessels; c The image after a posteriori shading correction
filter; d The second parallel phase after the Laplacian filter; e The
result after the conversion to an 8-bit image; f The result after the
skeletonization process; g The corresponding histogram of non-
vascularized meshes/mm2 (surface distribution of non-vascularized
regions). Adapted from [64]
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lymphatics are drained via paired thoracic ducts into the
jugulo-subclavian junction. Similarly to mammalian
lymphatics, the lymphatics of the CAM are characterized
by an extremely thin endothelial lining, pores, and the
absence of a basal lamina [81]. Molecularly, and in analogy
to the mammalian system, lymphatic endothelial cells in
the CAM are characterized by the expression of VEGFR-2
and -3 and are also Prox1 positive. Application of VEGF-
C, the ligand of these two receptors, on the differentiated
CAM, induces proliferation of lymphatic endothelial cells
and formation of enlarged lymphatic sinuses. Under normal
development, the sources of VEGF-C are the allantoic
epithelium and the wall of the larger blood vessels. The
fact that the lymphatics of the CAM travel along the side of
the larger blood vessels (Fig. 6) indicate that the high level
of VEGF-C from the wall of these vessels contributes to
pattern the normal distribution of lymphatics in the CAM.
The presence of a lymphatic system in the CAM opens the
possibility of studying its function and response to a large
number of compounds. Lymphatics have been shown to
remodel in response to pathological conditions and play a
critical role in tumor metastasis [82]. Papoutis et al. [83]
studied the effects of two rat tumor cell lines (C6 glioma
and 10AS pancreatic carcinoma) that differ in their VEGF-
C expression profiles. Whereas the 10AS cell line expres-
ses high levels of VEGF-C, the C6 glioma cells only
weakly express VEGF-C. They showed that only the 10AS
cells induce lymphangiogenesis.
Assessment of vascular permeability, tumor growth,
and metastasis
Vessel permeability
The permeability of the vasculature can be assessed in real-
time using the traffic of fluorescent dextrans of various
molecular weights i.e. macromolecular drug carriers
(70 kDa) and antibodies (150 kDa) into the tumor inter-
stitial space. Whereas large dextrans of 2,000 kDa are
sequestered within the lumen of the tumor vasculature [84,
85]. These alternative sizes of dextrans offer real-time
monitoring power to study vascular leak in the CAM
vasculature during the sequential development phases of
endothelial proliferation (angiogenesis), cytodifferentiation
and senescence [86–88]. It also provides the ability to
determine the pharmacodynamics and pharmacokinetics of
drugs diffusing from the CAM vasculature [89] or in
response to engrafted tumor explants [85]. Regional and
temporal differences in vessel permeability within the
tumor microenvironment may also be captured at high
resolution using an intravital imaging approach.
An enhancement of the vascular permeability in the
CAM has been studied using VEGF [90] or techniques
such as low-dose photodynamic therapy [20] or a low-
frequency contrast material-enhanced ultrasound on the
vascular endothelium [91]. In the latter studies diameter of
affected vessels, number of extravasation sites, extravasa-
tion rate, area, and location, as well as changes in endo-
thelial cells and basement membrane were evaluated.
Tumor growth, and metastasis
During past three decades several studies have reported
successful use of the CAM in cancer biology and tumor
angiogenesis (Table 5). The first report of an angiogenic
response in the CAM was induced by Jensen Rat Sarcoma
and was described in 1913 by Murphy [92]. To date many
tumor cells placed on the CAM have been shown to engraft
and follow all steps of tumor progression: grow, angio-
genesis, invasion, extravasation and metastasis. The spon-
taneous metastatic events occurring after cell inoculation or
intravasation into the vasculature has provided valuable
information to understand tumor progression and meta-
static potential of specific cell lines/primary tumor
fragments.
Table 5 summarizes the cell types successfully grown
on the CAM. Moreover, the vascularization of neoplastic
and normal tissue fragments, either fresh or cryopreserved,
grafted on the CAM has been evaluated in detail [71].
The highly vascularized network of the CAM sustains
tumor viability and within a few days after cell grafting
(Fig. 7) it can offer the means to study intravascular
invasion of tumor cells in vivo [23, 73, 107]. In fact,
trafficking of tumors cells in the chicken embryo has been
shown by real-time imaging [73]. Furthermore, since the
CAM is an isolated system, the half-life of many molecules
such as small peptides tends to be much longer in com-
parison to mammalian models, allowing study of potential
anti-metastatic compounds that are only available in small
quantities [73, 93]. Table 6 summarizes tumor types shown
to metastasize in the CAM.
Another mechanism of cell dissemination that takes
place along the blood vasculature is called vasculotropism.
In this process tumor cells appear to grow along the exis-
tent blood vessels, rather then randomly distributed within
the CAM mesoderm. This was shown for human HT-1080
fibrosarcoma [110], human A2780 ovarian carcinoma
(Nowak-Sliwinska P, unpublished data), and human mel-
anoma [113].
Selective anti-vascular therapies and diagnosis
Photodynamic therapy
The well-vascularized surface of the CAM has several
advantages as a model for studying the vascular effects of
Angiogenesis (2014) 17:779–804 789
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photodynamic therapy (PDT). PDT is based on the inter-
action of a systemically or topically applied photosensi-
tizing agent (photosensitizer, PS) with molecular oxygen
after irradiation with light of an appropriate wavelength
[114]. The initial reaction, leading to generation of reactive
singlet oxygen, activates a cascade of chemical and
Table 5 Tumor cell lines and tumor tissue successfully used in the CAM to study tumor growth
Type Inoculation technique Administration Ref.
Tumor cell lines
Human ovarian carcinoma (A2780) Spheroid Topical [39]
Non-metastatic human colon carcinoma (SW480) Suspension serum-free medium i.v. [93]
Human colorectal cancer (HTC-116) Matrigel Topical [32]
Human sarcoma (Saos-2 and SW1353) Matrigel [94]
Human clear cell renal cell carcinoma (CCRCC) Suspension in medium [95]
Osteosarcoma (various types) [96]
Murine melanoma B16-F10 [97]
Human myeloma plasma cells Suspension in medium adsorbed
on a gelatin sponge
[98]
Head and neck squamous cell carcinoma (HNSCC) and peripheral blood
mononuclear cells (PBMC) co-culture
Cell culture insert [99]
Tumor tissue
Walker 256 carcinosarcoma 1–1.5 mm tissue fragments Allantoic
cavity
[71]
Human sarcoma 1–1.5 mm tissue fragments Topical [94]
Mouse teratoma, mouse C57 melanoma, rabit V2 carcinoma [100]
Meningioma, glioblastoma Lyophilized pieces [101]
Neuroblastoma 1–2 mm fragment [101]
Hepatocellular carcinoma Fragment [102]
Human M21-L melanoma, S100 melanoma 50 mg fragment [103,
104]
Human ovarian adenocarcinoma 3–8 mm fragment [105]
Cryopreserved human ovarian adenocarcinoma 1–2 mm fragment [106]
Table 6 Tumor cell lines shown to exhibit spontaneous cell intravasation, vasculotropism and metastasis in the CAM
Cell type Inoculation technique Administration Ref.
Human neuroblastoma (IMR-32) Serum-free medium and
matrigel
Topical [108]
Human epidermoid carcinoma, human sarcoma, human embryonal
rhabdomyosarcoma
Explanted Subcutaneous [16]
Rat sarcoma Explanted Into the CAM [92]
Human epidermoid carcinoma (HEp-3) Suspension Topical [109]
Estrogen receptor negative (MDAMB231) and positive (MCF-7) breast
adenocarcinoma
[109]
Androgen receptor negative (PC3) and positive (LNCaP) prostate
adenocarcinoma
[109]
Human fibrosarcoma (HT-1080) [93, 109]
[110]
Human ovarian carcinoma (OVCAR-3, SKOV-3 and OV-90) [111]
Human embryo fibroblasts (HEF) [109]
Human colon carcinoma metastatic (SW620) and non-metastatic (SW480) Suspension in serum-free
medium
i.v. [93]
Rat C6 glioma and 10AS pancreatic carcinoma Suspension in medium Topical [83]
Human Burkitt’s lymphoma (BL) Matrigel [112]
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physiological responses, which results in a temporary or
permanent occlusion of the irradiated vasculature [115].
The angio-occlusive effect of PDT in the CAM has been
has been monitored and described in detail by Debefve
et al. [51].
Various light sources [29] and different types of
photosensitizers have been tested on the CAM model [116–
119] enabling the comparison between different treatment
conditions. The photosensitizers can be administrated in
the CAM intraperitonealy [120], topically [121] or, most
often, intravascularly [18, 20, 42, 116, 117, 122]. Since the
photosensitizers are usually hydrophobic, to facilitate its
administration, they are distributed in the form of lipo-
somes [123] [117], biocompatible solvents like N-methyl-
pyrrolidone, as well as 0.9 % sodium chloride [124]. In
addition, polymeric nanoparticles were also used for this
purpose (e.g. poly(lactide-co-glycolide, PLGA or PLA)
[118]. An overview of delivery systems tested on the CAM
is listed in Table 7.
Photodynamic therapy (PDT) is known to provoke an
angiogenic response [115]. Therefore its combination with
a variety of topically [19, 42, 140–142] or intravenously
administered [32] anti-angiogenic compounds have been
studied using the CAM for their ability to suppress vascular
growth.
The CAM was also exploited to determine the rela-
tionship between the progression between tissue oxygen
concentration during PDT and the resulting vascular
damage. Measuring the local pO2 is also of interest for
other types of treatments, such as radiotherapy or photo-
dynamic therapy, as it is well established that tissue oxy-
genation plays an important role on the outcome of such
treatments. The measurements of the pO2 in the CAM was
performed, using a micro-O2-electrode [143], the delayed
fluorescence [121] or luminescence quenching of a ruthe-
nium derivative [144] monitored with a dedicated optical,
fiber-based, time-resolved spectrometer or a fiber-optic
oxygen sensor [32].
Low-dose PDT enhances vessel permeability, therefore
might be used as a drug delivery method [145]. The per-
turbation of endothelial cell membranes by PDT results in
the loss of tight junctions responsible for the sealing
properties between adjacent cells, and consequently leav-
ing enlarged gaps between cells that increase the vascular
Table 7 Drug delivery systems tested on the CAM
Delivery system Delivered drug Ref
Immunoliposomes Coupled to a mAb targeting tumor cells (anti-GD2) Doxorubicin, AC [125]
Liposomes Dipalmitoylphosphatidylcholine (DPPC) Meso-tetra(m-hydroxyphenyl)chlorin (PS) [117]
(hydro)gels Amiloride Sucrose acetate isobutyrate (SAIB) and calcium
alginate
[126]
Poly(ethylene glycol)-vinyl sulfone cross-linked
with albumin
Spongosine 1-phosphate (S1P), LF [127]
3D grafts type I fibrillar
collagen
Collagen onplants GFs, A, AA [30]
Collagen matrices Collagen covalently linked with heparin VEGF [128]
Conjugates with drugs Polyvinylpyrrolidone PS [129]
Nanoparticles Poly(d,l-lactic acid) Meso(p-tetracarboxyphenyl)porphyrin (PS) [130]
Nanoparticles Poly (lactide-co-glycolide) Tetraiodothyroacetic acid [131]
Peptides Cell-penetrating peptides (bioportides) Peptides, proteins, and oligonucleotides [132]
Microspheres Poly (d,l-lactic acid) Taxol (AC) [133]
Microspheres Poly(epsilon-caprolactone) paclitaxel (AC)
Filter disks Methylcellulose, nitrocellulose, Whatman paper AA, PA, GF [56]
Pellets Ethylene–vinyl acetate (EVA) copolymer – [134]
Liposomes Phosphatidylocholine Polyvinylpyrrolidone-iodine (AM) [135]
Scaffolds Poly(D,L-lactic) acid (PLA) VEGF165, bFGF [136,
137]
Surface-engineered
dendrimers
Arginine conjugated poly(propylene)imine
dendrimers
Doxorubicin hydrochloride (AC) [138]
Bio-hydrogels Fibrin bio-hydrogel Genetically engineered cells over-expressing
VEGF
[139]
PS photosensitizer, AA anti-angiogenic, A angiogenic, AC anti-cancer, AM anti-microbial, ECs endothelial cells, GF growth factor, LF lipid
factor
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permeability to macromolecules following PDT. This
principle is currently being applied for targeted delivery of
chemotherapy, as the injection of a reduced amount of a
chemotherapeutic drug could be effective due to enhanced
local delivery rendered possible by combining Visudyne-
PDT with aspirin [86].
Photodynamic diagnosis
Photodynamic diagnosis (PDD) of cancer using photosen-
sitizers is one of the major advances as a new technique for
early cancer detection. The clinical application of hypericin
(HY) or aminolevulinic acid (ALA) and its derivative
Hexvix has been demonstrated to improve visualization
of urological cancers as compared to white light cystos-
copy [146]. This light-induced fluorescence after treatment
is an experimental model used in the early diagnosis of
cancerous disorders in urology. Malik et al. [147] con-
ducted an in vivo study evaluating the ALA-based fluo-
rescence diagnosis of endometric implants on the CAM.
Saw et al. [148] reported on the hypericin-N-methyl pyr-
rolidone (HY-NMP) formulations in the CAM inoculated
human bladder cancer cells as a potential fluorescence
diagnostic agent. The NMP formulations investigated were
able to produce significantly higher contrast for tumor
tissues and at earlier time points than was possible with HY
in albumin. MPEG-hexPLA micelles were successfully
used as hypericin carriers for ovarian cancer diagnostics
[149].
Laser photoangiolysis
Selective vascular ablation (photoangiolysis) using pulsed
lasers that target hemoglobin is an effective therapeutic
strategy for many lesions residing in the thin tissue that
forms the vocal folds. However, vessel rupture with
extravasation of blood reduces selectivity for vessels,
which is frequently observed with the 0.45-ms, 585 nm
pulsed dye laser. The CAM has been useful predicting the
effects of photoangiolytic lasers on the vocal fold micro-
vasculature. Specifically, the CAM has been explored to
test the effects of distinct laser settings, modes of delivery,
active cooling, and wavelengths. Such information has
been essential for optimizing the effectiveness of lasers in
treating laryngeal pathology while preserving vocal func-
tion. One example is the 980 nm Gold laser that achieved
selective vessel coagulation [150]. In other study, the
pulsed 532 nm potassium-titanyl-phosphate laser was used
to achieve selective vessel destruction without rupture
using the CAM under conditions similar to flexible laryn-
goscopic delivery of the laser in clinical practice. It was
shown that this treatment was effective for ablating
microcirculation while minimizing vessel wall rupture and
hemorrhage [151].
Radiotherapy
A few reports have used the CAM in radiotherapy-related
studies. Interestingly, chicken embryos are able to tolerate
high dose of X-rays under single or multifractionated
irradiation, an obvious advantage for these studies. Not
surprisingly X rays have been shown to decrease the
number of blood vessels, most probably due to vascular
targeting within the first hours after irradiation [152].
However, it appears that X-rays promote multiple effects in
the CAM: (1) induce early apoptosis of CAM cells, a
property that can be exploited to screen radioprotective
compounds [153], (2) modulate the synthesis and deposi-
tion of extracellular matrix proteins involved in regulating
angiogenesis and (iii) affect angiogenesis induced by tumor
cells implanted onto the CAM [154]. More recently, the
CAM/embryos has been used to test the activity of radio-
sensitizers. For example, etanidazole, a well-known hyp-
oxic cell radiosensitizer, was evaluated using tumor-
bearing chick embryos [21].
Distinct modalities of X-ray beams have also been
evaluated in the CAM. In particular, microplanar beams
(microbeam radiation, MR) have been compared to broad
beams (seamless radiation) [155]. MR promotes capillary
damage, with tissue injury caused by insufficient blood
supply. Vascular toxicity and physiological effects of MR
depend on the stage of capillary maturation and appear
within the first hour after irradiation. The authors noticed a
dose dependent vacuolization of endothelial cells as well as
growth retardation, resulting in a remarkable reduction in
the vascular endpoint density. Finally, several preclinical
studies in the CAM have used combination therapy and
demonstrated an increased effectiveness when radiotherapy
is combined with an anti-angiogenic treatment [156, 157].
Combined effects of paclitaxel and single or fractionated
doses of ionizing radiation during angiogenesis were also
evaluated [22]. X-rays suppression of angiogenesis
includes anti-proliferative action and induction of nitric
oxide (NO) which also inhibits vascular growth [158].
These results suggested that NO is involved in the anti-
angiogenic mechanism of X-rays and that pharmacological
manipulation of NO may offer an alternative therapeutic
approach for treating pathological conditions involving
angiogenesis [159].
Vascular disrupting agents
Vascular disrupting agents (VDA) that destroy irregular
tumor blood vessels often exhibit an immediate impact on
the vasculature of tumors provoking their collapse after a
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few applications. They are usually small molecule com-
pounds that bind to the colchicine binding site of tubulin
and cause extensive cytoskeletal rearrangements of the
microtubules and the actin bundles in endothelial cells
[160, 161]. Disruption of small blood vessels, as well as
hemorrhages as a result of leaking or broken vessels were
observed shortly after administration of VDAs, e.g. ve-
rubulin [162], or the microtubule-depolymerizing agent C9
[163]. Moreover, the growth of solid tumors on the surface
of the CAM was successfully inhibited by VDAs, e.g.
phenyl-3-(2-chloroethyl) urea [164]. New compounds with
both, anti-angiogenic and vascular-disrupting properties
have been also frequently tested in the CAM model (i.e.
deoxypodophyllotoxin [165], vinblastine [166], combre-
tastatin A-4 or its gold derivative [167] ).
Drug delivery systems, drug pharmacokinetics
and biodistribution
Drug delivery systems (DDS) aim to distribute therapeutic
agents to specific sites of injury or disease. Research on
DDS includes: (1) the direct modification of the therapeutic
agents to form drug conjugates, (2) the encapsulation of the
therapeutic agents into micro or nanosized structures, and
(3) the encapsulation or conjugation of the therapeutic
agents into scaffolds. Most commonly, these different DDS
are studied in vitro with cells in culture and then tested in
pre-clinical animal models. However, the leap from in vitro
cultured cells to in vivo pre-clinical animal models often
leads to unsatisfactory performance which is frustrating
due to the high cost of the pre-clinical studies. The CAM
has been an excellent platform to test multiple DDS for-
mulations concurrently, thus it has been used as an inter-
mediate step between in vitro analysis and in vivo pre-
clinical evaluation in mammals [168].
Pro-angiogenic drugs
In tissue repair, the controlled induction of angiogenesis
directed at afflicted sites (ischemic tissue) is of great
importance. To test the pro-angiogenic activity of different
DDS, investigators frequently apply them directly onto the
CAM surface and proceed to monitor the angiogenic
response. These pro-angiogenic agents can be delivered as
drug conjugates, as micro or nanoparticles, or as part of a
tissue scaffold. For example, the delivery of growth factors
such as VEGF121, VEGF165, and FGF-2 to induce an
angiogenic activity has been extensively studied [6, 36,
128, 136]. Using the CAM assay, researchers have been
able to screen different formulations to find that the indi-
vidual delivery of each of these factors entrapped within a
matrix results in the formation of highly leaky vessels
[169], whereas the delivery of combinations of these
factors or the immobilization of VEGF (either 121 or 165)
yields vessels with normal morphology and adequate bar-
rier performance (non-leaky vessels).
Anti-angiogenic drugs
The efficiency of formulations containing anti-angiogenic
drugs with the CAM model may be easily evaluated by
determining degree of vascular occlusion [30, 56, 125].
Efficacy of paclitaxel, delivered via various types of for-
mulations, was studied on the CAM and elegantly reviewed
by Vargas et al. [170]. Recently, surface-engineered den-
drimers were used for tumor specific delivery of doxoru-
bicin hydrochloride [138]. The later system enabled an
initial rapid release followed by sustained release of
doxorubicin hydrochloride with significant anti-angiogenic
activity. Tetrac (tetraiodothyroacetic acid) covalently
linked to poly (lactide-co-glycolide) as a nanoparticle
arrested tumor-related angiogenesis and human renal cell
carcinoma growth in the CAM model [131].
Biodistribution
Drug pharmacokinetics can be assessed using the blood
sampling or selected organ extraction of fluorescence
detection (in case of fluorescent drugs). The later method is
widely used with direct fluorescence measurements in the
CAM vasculature in vivo [20] or in ex vivo via tissue
fluorescence analysis [171]. Due to the small organ size
and low blood volume, both development-stage dependent
[172] sensitive analysis methods should be used. Conse-
quently, non-invasive methods such as biosensors (e.g.
glucose [139]) for the analysis of drug concentration can be
advantageous in this model.
Gas/ion transportation
As previously alluded to, the CAM functions as ‘‘the lung’’
of the avian embryo, and thus, it is responsible for gas
exchange, but it also provides calcium transport from the
eggshell into the embryo, it offers acid–base balance, and it
mediates regulation of water, and electrolyte resorption
from the allantoic cavity where urinary waste products are
discharged.
The CAM is involved in the transport of sodium and
chloride from the allantoic sac and calcium from the egg-
shell to the vasculature. Through dilation of the associated
blood vessels (known as chorioallantoic vessels), the
embryo is able to thermo-regulate and avoid overheating
for long periods of time. Several studies related to gas and
water exchange have been reported. For example, the
functional role of hypoxia in vascular flow was nicely
explored in the studies published by Lindgren and
Angiogenesis (2014) 17:779–804 793
123
colleagues (128). Initially, the CAM performs gas-
exchange functions via the area vasculosa, the main
respiratory organ before day 6 [173], but this is gradually
substituted by the CAM vessels. By day 14, the CAM
capillary network is completely developed and by day 19
the embryonic lung ventilation starts as the CAM degen-
erates and the embryo hatches. Lindgren et al., showed that
a one-time change in oxygenation of the external micro-
environment between day 15 and day 19, could affect
blood flow. Local hypoxia yield direct vasoconstriction,
increasing the flow [174], demonstrating that ventilation is
associated with perfusion.
In terms of calcium, the chorionic epithelial cells
transport Ca2? to the embryonic circulation at an impres-
sive rate: 100 nmoles of calcium per hour for 1 cm2 of the
CAM surface. The mechanism of this transport seems to
rely on the sequestration of calcium within endosome-like
vesicles upon the initial uptake phase [94]. Interestingly,
in vitro CAM ectodermal cells exhibit faster calcium influx
rates when compared to human erythrocytes suggesting
alternative calcium entry mechanisms [175]. This unidi-
rectional process was shown to be highly specific for Ca2?
and regulated by vitamins D and K [176]. A detailed
review of transepithelial ion transport through the chori-
onic epithelium has been described elsewhere [35].
Allergenicity and toxicity
The worldwide objection to the use of animals in testing of
irritants and cosmetics makes the development of a system
that does not use mammals highly desirable. Below are
some important examples.
Skin irritation
A number of in vitro methods to assess skin and eye irri-
tation/corrosion have been developed as alternatives to the
in vivo rabbit tests [177]. Human skin models, like Epi-
SkinTM and SkinEthicTM, that closely mimic the bio-
chemical and physiological properties of the upper parts of
the human skin, have undergone extensive formal valida-
tion and acceptance procedures in order to be broadly
applicable. In Europe, the CAM and the cornea pocket
assay have also been accepted for this purpose. In the
CAM, potential for irritation can be assessed with specific
read-outs on the membrane and/or vessels (hemorrhage,
lysis, coagulation, changes small vessel diameter [178]),
which is then compared to the effect of 5 % sodium
magnesium lauryl-myristyl-6-ethoxysulphate [179].
The chimeric skin-CAM system serves as a promising
alternative to current animal-based sensitization approa-
ches, particularly when using human grafts. The first report
of a successful human skin graft onto the CAM was
described by Goodpasture [58]. An important advantage of
the CAM on skin engrafts as compared to in vitro models
of organotypic skin explants is that the skin is maintained
in a more ‘‘physiological status’’, meaning dependent on
vessels for its oxygenation. By having a continuous blood
supply, the grafted skin remains viable for the same length
of time as chick embryo survival. Furthermore, epidermal
Langerhans cells (LC) are retained in the epidermis for
several days after grafting into the CAM, unlike in orga-
notypic explants [179]. Slodownik et al. used allergens to
evaluate the LC as a measure of their allergic potency. All
agents with known allergic potential induced statistically
significant migration of LC [180].
Eye irritation
Ocular tissues, such as the cornea and conjunctiva, are
susceptible to injuries and adverse effects, either from
administered drugs or additives used in pharmaceutical
products [181, 182]. Assessment of the toxicity of oph-
thalmic formulations and the potential for ocular irritation
represents an essential step in the development of new
ocular delivery systems.
The CAM has replaced the highly controversial ‘‘Draize
eye irritancy test’’ used to determine the irritation potential
of cosmetics by placing liquid, flake and powdered sub-
stances into the eyes of rabbits. The hen’s egg test (HET–
CAM) provides a platform for conjunctival irritation test-
ing, as it responds to irritant substances with an inflam-
matory reaction similar to that seen in conjunctival tissue
[183–185]. Various studies included classification of sev-
eral classes of irritants, ranging from non-irritant to severe,
with high correlations between the systems. This devel-
opment was encouraging since it suggested that in vitro
models could provide valid alternatives for prediction of
ocular toxicity [186]. After the application of the test
substance (e.g. cholesterol or naltrexone), blood vessels are
examined for irritant effects at different time points post-
application. The evaluation includes assessment of hy-
peraemia, hemorrhage and clotting [187]. A time-depen-
dent numerical score is then attributed to each test
substance or formulation, to give an irritation score that
ranges from slight to severe [187, 188]. A modification of
the HET–CAM assay was introduced by Hagino et al.
[189] who used trypan blue to determine degree of cell
death. Trypan blue has been used in many biological sys-
tems to distinguish between living and dead cells. As the
amount of trypan blue adsorbed by the CAM can be
measured spectrophotometrically, the quantification is
simple and reproducible. When compared by simple linear
regression, the degree of trypan blue adsorbed by the CAM
and that obtained from Draize eye irritation test in the
cornea presented high correlation coefficients, indicating
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that the CAM can be an excellent choice for predicting
corneal injury without compromising quality.
The CAM has also been used as a model in surgical retinal
research [190]. In fact, several of the new surgical tools,
techniques for coagulating retina, microinjection, cannula-
tion techniques, and endoscopic surgery were first tested in
the CAM and subsequently evaluated in animal models.
Microrobots that are used for intravitreal delivery of as well
as other surgical applications were first evaluated on the
CAM [191] prior to further testing into a rabbit eye [192].
Organ transplantation and tissue engineering
Due to its immunodeficiency prior to day 15 post-fertil-
ization [13], the CAM has been extensively used to eval-
uate allogeneic and xenogeneic transplantations. In fact,
the CAM is considered as a suitable model to study the
implantation/biocompatibility process and to explore dif-
ferentiation of tissue implants. It has also been used to
evaluate tissue remodeling within or in response to the
implanted material, regeneration events, and neovascular-
ization. These processes depend on the mechanical and
physico-chemical properties of the implanted material
[178]. Already in 1916, for the first time, multiple chicken
tissues were grafted in the chicken embryos [193]. More
recently, allogeneic and xenogeneic tissues were success-
fully grafted on the CAM, such as liver [194], proliferative
endometrium [195], adrenal gland or cerebellum [196], or
intact human skin [58, 177], see Table 8.
Transplanted tissues can survive and develop in the
CAM by either peripheral anastomoses between implanted
graft and original CAM vasculature or by new angiogenic
growth from the CAM into the transplant. It has been
demonstrated that the formation of peripheral anastomoses
between pre-existing donor and host vessels is the most
common, mechanism involved in the revascularization of
embryonic grafts [71]. The assembly of graft and CAM
blood vessels occurs between relatively large arteries or
veins, resulting in chimeric vessels of varying morphology
[203].
The CAM has been also used in stem cell research in
which various extracellular matrices or synthetic polymer-
derived scaffolds have been evaluated in an effort to con-
struct desired tissue-like structures [173, 176, 198]. The
combination of biocompatible materials and stem cells
appears to be a future trend that might prove fruitful in
comparison to other systems, in large part, due to the
neovascular properties of the CAM.
To date tissue engineering has been successful in pro-
ducing simple avascular tissues, such as skin and cartilage,
which are thin enough for oxygen and other nutrients to
diffuse passively. To sustain a tissue with large dimensions
(greater than 400 lm in thickness), a vascular supply that
effectively permeate the implant is essential [204]. How-
ever, caveats are also inherent to the system. In particular,
inflammation and ulceration might occur in response to
implants of non-biological materials. The next generation
of tissue engineering products has been largely designed to
promote timed release of growth factors and to achieve
biocompatibility without promoting inflammation. More-
over, several technologies have been used to evaluate the
biocompatibility and/or inflammatory response to bioma-
terials implanted [34]. More recently the use of mathe-
matical models for tissue-engineered angiogenesis that
takes into account the interactions between several of the
participating cell types into a porous scaffold has provided
important insights to more effectively test and evaluate
models of interaction [198].
CAM as a tool to study vascular development
Physiological angiogenesis
The ease and accessibility of the CAM is undisputed. Thus,
studies that aimed at evaluating the effect of environmental
Table 8 The CAM model in transplantations and tissue engineering
studies
System Material Ref.
Transplants Chicken liver [194,
197]
Human skin [58,
179]
Chicken or quail embryos adrenal gland
or cerebellum
[196]
Human proliferative endometrium [33,
195]
Human ovarian tissue [108,
109]
Cells Murine embryonic stem cells (in gelatin-
microbubble scaffold)
[198]
Mouse pulmonary stem/progenitor cells [173]
Human dental pulp stem cells (in
matrigel)
[176]
Rat nodose ganglion neurons [199]
Human kidney-derived cells (in
matrigel)
[174]
Tissue-
engineered
matrices
Human femoral cancellous bone chips [84]
Chicken bone scaffolds [200]
Bioactive glass ceramic scaffolds
improving the growth and
mineralization of skeletal components
[201]
3D co-cultures of osteoblasts and ECs in
DegraPol foam
[202]
Acetaminophen biosensors [35]
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factors in vascular development have taken advantage of
this system in a manner that could not be achieved in
mammalian systems. Exposure of CAMs to different
degrees of CO2 [205] and O2 [68, 206], for example, have
demonstrated the impact of gases on vascular development.
While hypoxia and hyperoxia will be discussed more in
detail below, this constitutes a classical example of how the
system can be exploited to clarify environmental effects on
vascular growth. Similarly, hyperglycemia has been eval-
uated through a simple process: intravitellus glucose
injection [61]. Interestingly, the investigators reported that
hyperglycemia decreased angiogenesis as early as day 5
and found a significant increase in apoptosis and pericyte
association as early as 2 days post-treatment [61]. These
results are consistent with recent findings indicating the
negative role of hyperglycemia in angiogenic responses
through increase of reactive oxygen species and limitation
of VEGFR2 at the cell surface [207].
The CAM has also been used to study localization and
levels of molecules in relation to their angiogenic/quiescent
status [40, 208–212]. Thus, it has served as a valuable
model system in which to validate expression of relevant
vascular molecular pathways. In addition, quail-chicken
chimeras have been extensively used to answer questions
related to vascular development. For example, the relative
plasticity of arterial and venular endothelium has been
tested using quail grafts into chicken coelom that acted as
hosts. In these experiments, the investigators found that
endothelial cells from the grafts of distinct vessels remain
plastic even after the acquisition of molecular markers for
arteries and veins [213].
Unfortunately, lack of avian-specific reagents (as well as
the initially limited genomic information) provided hin-
drance to a more robust use the CAM in developmental
studies of physiological angiogenesis. In this regard, the
recent expansion of retroviral, lentiviral and adenoviral
vectors for genomic modification of CAM cells has offered
significant advantages to this system [214]. Thus, dominant
negative constructs and other tools have been developed to
explore the contribution of specific growth factors and
signaling cascades in the CAM, in addition to the standard
local administration of the growth factor. For example,
using manipulation of FGF1 levels, Forough and col-
leagues showed that neovascularization stimulated by
FGF1 could be reduced by selectively targeting AKT sig-
naling [215].
Hypoxia and hyperoxia
Hypoxia during embryogenesis may induce changes in the
development of some physiological regulatory systems,
thereby causing permanent phenotypic changes in the
embryo. Various levels of hypoxia at different time points
during embryogenesis were found to affect both anatomical
and physiological morphogenesis. Druyan et al. demon-
strated that after the 12 h of hypoxic exposure on the CAM,
expression of HIF1a, MMP2, VEGF, and VEGFR2 was
significantly higher in hypoxic (17 % O2) embryos than in
controls. In day 6 expression of HIF1a, VEGF, and FGF2
was significantly higher in hypoxic embryos than in con-
trols [216].
Strick et al. conducted the morphometric measurements
of chorioallantoic membrane vascularity in chicken eggs
that were incubated in various oxygen atmospheres (12, 16,
21, 45, or 70 %) beginning on day 7, and vascularity was
measured at day 14 [217]. They concluded that hypoxia
stimulates and hyperoxia inhibits angiogenesis in the CAM
in a dose-related manner. Burton and Palmer showed that
hypoxia (17 % O2) reduced embryo and CAM growth, but
accelerated maturation of the capillary plexus. Hyperoxia
(40 % O2) had a less marked effect but appeared to retard
the final invagination of the plexus, resulting in a thicker
air-blood barrier [218].
Intussusceptive angiogenesis
While most of the growth of the CAM vasculature occurs
through sprouting angiogenesis, towards the end of vas-
cular expansion and associated with remodeling processes,
intussusceptive microvascular growth also occurs. The
process of intussusception is one by which capillaries are
generated via the intravascular division of the lumen. This
occurs through the growth of thin intraluminar walls (pil-
lars) that proceed to fuse with the opposite side of the
vessel. In this manner, the insertion of transcapillary pil-
lars, provides a means to divide vessels further increasing
the complexity and number of individual vessels in the
vascular plexus. The pillars increase in thickness to include
fibroblasts and extracellular matrix increasing in girth and
ultimately contribute to separate the vascular segment into
two fully independent vessels.
While pillars are discrete structures within the blood
stream, relatively isolated from extravascular soluble tissue
factors, that are not only identifiable by intravital 2D
imaging, but amenable to detailed morphometric analysis.
Recent studies have indicated that the number of pillars is
the highest between day 8–10 of CAM development and
that they are exquisitely responsive to levels of VEGF
[219–221]. The pillars are lined with normal-appearing
endothelium suggesting a normal responsiveness to intra-
luminal flow fields [222]. The effect of mechanical forces
in shaping pillar geometry, suggested their potential role in
initiating pillar formation and potentially explain why they
only occur later in CAM development. Most pillars, par-
ticularly at vessel bifurcations, demonstrated only small
changes in geometry during culture. Lee et al. [223] in their
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study on physical forces on the CAM concluded that these
spatial dynamics reflect a responsiveness of blood vessels
to intravascular flow fields and indicate the importance of
mechanical forces in shaping both intussusceptive angio-
genesis and vessel structure in the microcirculation.
Vasculogenic mimicry
Vasculogenic mimicry (VM) a process by which tumor
cells acquire functional features of endothelium and con-
tribute to the formation of the vascular wall has been
successfully studied in the CAM [224]. Ribatti et al. [97]
showed for the first time the occurrence on VM in the
melanoma grafted CAM model after implanting B16-F10
melanoma cells. Since, VM represents an alternative
mechanism of tumor vascularization in which tumor cells
actively participate in the formation of blood vessels. Its
demonstration in the CAM provides an important valida-
tion step that can be further explored.
Physical forces in the CAM
Hemodynamic forces, including vascular circumferential
tension and shear stress, have been predicted to influence
angiogenesis. Recently, Branum and colleagues tested this
hypothesis directly by evaluating the effect of pharmaco-
logical induction of acute and chronic bradycardia in
chicken embryos. Contrary to predictions, the investigators
found that vascular density of smaller vessels was reduced,
but larger vessels were not significantly affected [225].
In terms of vascular remodeling, physical forces are also
known to contribute to the progression of the uniformed
primary plexus into a hierarchic vascular tree. It is also
known that arterialization of veins can occur when sub-
jected to high shear stress forces. For example saphenous
veins used in coronary bypass grafts to substitute occluded
arteries show signs or arterialization. Using the CAM,
investigators have explored whether molecular identity of
arteries and veins is also governed by flow. In an elegant
series of experiments le Noble and colleagues showed that
arterial-venous differentiation is in fact a flow driven
highly dynamic process that relies on the plasticity of the
endothelium [226].
In addition to genetic and biochemical signaling, the
expansion and remodeling of a vascular supply is con-
trolled by microenvironmental signals such as mechanical
forces conveyed by extracellular matrix (ECM) and by
flow. Although capillary development is driven by angio-
genic mitogens, cell sensitivity to them might be modu-
lated by a complex set of physical interactions between
cells and ECM that alter the cellular cytoskeleton [227].
Changes in capillary cell shape and function can be pro-
duced by altering ECM elasticity or topography, as these
provide mechanical stresses that impact traction forces
[228]. Mechanical forces may also stimulate vascular
remodeling and capillary growth in vivo [229, 230]. Ki-
larski et al. [230] found that tissue tension is generated by
activated fibroblasts or myofibroblasts during wound con-
traction followed by the induction of new vasculature.
These mechanical forces pulled vessels from the preexist-
ing vascular bed with functional circulation that expanded
as an integral part of the growing granulation tissue
through vessel enlargement and elongation.
The mechanical forces associated with blood flow
include wall shear stress (the frictional force tangential to
the vessel wall) and circumferential strain (a blood pressure
related force perpendicular to the direction of flow); wall
shear stress being the dominant mechanical force in the
smooth and continuous flow of the peripheral CAM
microcirculation [222]. Although wall shear stress cannot
be directly measured, numerical simulations enable not
only the calculation of wall shear stress but the mapping of
these mechanical forces to the vessel wall. The spatial
relationships revealed by these maps provide important
insights into the role of mechanical forces in shaping the
structure of vessels and alters their responses during
pathological conditions.
Closing remarks
Despite enormous volume of information generated by
in vitro tests, in vivo experimentation offers a stronger
reliable value when assessing angiogenic responses.
In vivo assays usually require special skills and ethical
committee approvals, thereby limiting the number of tests
that can readily be performed. As presented in this review,
the CAM model has been used effectively by several dis-
ciplines including biology, medicine and bioengineering to
determine vascular responses and to explore questions
related to blood vessel and lymphatic morphogenesis and
physiology. Numerous and continuous improvements in
imaging and quantification continue to offer strengths to
the model. Furthermore, while not mammalian, the CAM
offers a valuable intermediate step that is both cost and
time-efficient. Finally, considering the pressures with
minimizing the use of animal models and following the
‘‘3R’’ rule (Replacement, Refinement and Reduction) the
CAM provides an excellent intermediary step prior to pre-
clinical evaluation.
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